1017575-23-3Relevant academic research and scientific papers
Side chain SAR of bicyclic β-lactamase inhibitors (BLIs). 1. Discovery of a class C BLI for combination with imipinem
Blizzard, Timothy A.,Chen, Helen,Kim, Seongkon,Wu, Jane,Young, Katherine,Park, Young-Whan,Ogawa, Amy,Raghoobar, Susan,Painter, Ronald E.,Hairston, Nichelle,Lee, Sang Ho,Misura, Andrew,Felcetto, Tom,Fitzgerald, Paula,Sharma, Nandini,Lu, Jun,Ha, Sookhee,Hickey, Emily,Hermes, Jeff,Hammond, Milton L.
scheme or table, p. 918 - 921 (2010/08/06)
Bridged monobactam β-lactamase inhibitors were prepared and evaluated as potential partners for combination with imipenem to overcome class C β-lactamase mediated resistance. The (S)-azepine analog 2 was found to be effective in both in vitro and in vivo assays and was selected for preclinical development.
NOVEL INHIBITORS OF BETA-LACTAMASE
-
Page/Page column 85, (2008/06/13)
A class of 7-oxo-2,6-diazabicyclo-[3.2.0]-heptane-6-sulfonic acid compounds substituted at the two position of the bicyclic ring with a heterocyclylaminocarbonyl group or a carbocyclylaminocarbonyl group are β-lactamase inhibitors. The compounds and their prodrugs and pharmaceutically acceptable salts are useful in the treatment of bacterial infections in combination with β-lactam antibiotics. In particular, the compounds are suitable for use with β-lactam antibiotics (e.g., imipenem and ceftazidime) against micro-organisms resistant to β-lactam antibiotics due to the presence of the β-lactamases.
